Stevens Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,588
| Closed | -$709K | – | 319 |
|
|
2026
Q1 | $709K | Buy |
+1,588
| New | +$740K | 0.11% | 108 |
|
|
2025
Q1 | – | Sell |
-2,058
| Closed | -$829K | – | 405 |
|
|
2024
Q4 | $829K | Buy |
+2,058
| New | +$954K | 0.33% | 84 |
|
|
2024
Q2 | – | Sell |
-2,668
| Closed | -$1.11M | – | 343 |
|
|
2024
Q1 | $1.11M | Buy |
+2,668
| New | +$1.13M | 0.22% | 103 |
|
|
2023
Q1 | – | Sell |
-869
| Closed | -$251K | – | 234 |
|
|
2022
Q4 | $251K | Buy |
+869
| New | +$265K | 0.16% | 108 |
|
|
2021
Q4 | – | Sell |
-9,972
| Closed | -$1.81M | – | 292 |
|
|
2021
Q3 | $1.81M | Buy |
9,972
+8,148
| +447% | +$1.59M | 0.76% | 31 |
|
|
2021
Q2 | $368K | Sell |
1,824
-2,605
| -59% | -$545K | 0.11% | 146 |
|
|
2021
Q1 | $952K | Buy |
4,429
+2,652
| +149% | +$583K | 0.52% | 36 |
|
|
2020
Q4 | $420K | Buy |
1,777
+631
| +55% | +$145K | 0.21% | 80 |
|
|
2020
Q3 | $312K | Sell |
1,146
-16,985
| -94% | -$4.69M | 0.12% | 93 |
|
|
2020
Q2 | $5.26M | Buy |
+18,131
| New | +$4.92M | 1.94% | 19 |
|
|
2020
Q1 | – | Sell |
-14,636
| Closed | -$3.21M | – | 447 |
|
|
2019
Q4 | $3.21M | Sell |
14,636
-17,016
| -54% | -$3.44M | 0.3% | 97 |
|
|
2019
Q3 | $5.36M | Buy |
+31,652
| New | +$5.6M | 0.48% | 62 |
|
|
2018
Q3 | – | Sell |
-54,397
| Closed | -$9.24M | – | 980 |
|
|
2018
Q2 | $9.24M | Buy |
+54,397
| New | +$8.43M | 0.33% | 85 |
|
|
2017
Q4 | – | Sell |
-81,819
| Closed | -$12.4M | – | 1058 |
|
|
2017
Q3 | $12.4M | Buy |
+81,819
| New | +$12.3M | 0.46% | 49 |
|
|
2017
Q1 | – | Sell |
-5,977
| Closed | -$440K | – | 1125 |
|
|
2016
Q4 | $440K | Sell |
5,977
-40,360
| -87% | -$3.28M | 0.02% | 607 |
|
|
2016
Q3 | $4.04M | Buy |
+46,337
| New | +$4.38M | 0.17% | 162 |
|
|
2016
Q2 | – | Sell |
-100,358
| Closed | -$7.98M | – | 1148 |
|
|
2016
Q1 | $7.98M | Buy |
+100,358
| New | +$9.08M | 0.32% | 99 |
|
|
2015
Q3 | – | Sell |
-27,897
| Closed | -$3.44M | – | 1234 |
|
|
2015
Q2 | $3.44M | Buy |
+27,897
| New | +$3.52M | 0.12% | 207 |
|
|
2014
Q2 | – | Sell |
-78,613
| Closed | -$5.56M | – | 1327 |
|
|
2014
Q1 | $5.56M | Buy |
+78,613
| New | +$6.23M | 0.15% | 165 |
|
|
2013
Q4 | – | Sell |
-95,336
| Closed | -$7.23M | – | 1248 |
|
|
2013
Q3 | $7.23M | Buy |
+95,336
| New | +$7.59M | 0.21% | 139 |
|
Other funds holding VRTX
Stevens Capital Management's VRTX Position: Q2 2026 in Review
Stevens Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,588 shares — an estimated $709K sold.
Stevens Capital Management first reported a position in VRTX in Q3 2013 and held it in 20 quarters. The position peaked at $12.4M in Q3 2017. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Stevens Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Stevens Capital Management sold 1,588 Vertex Pharmaceuticals shares in Q2 2026, an estimated $709K.
- Stevens Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 20 quarters.
- Stevens Capital Management's Vertex Pharmaceuticals position peaked at $12.4M in Q3 2017.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Stevens Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.